StockNews.com Initiates Coverage on Minerva Neurosciences (NASDAQ:NERV)

Analysts at StockNews.com began coverage on shares of Minerva Neurosciences (NASDAQ:NERV) in a report released on Tuesday. The brokerage set a “sell” rating on the biopharmaceutical company’s stock.

Separately, HC Wainwright reiterated a “neutral” rating and issued a $5.00 price objective on shares of Minerva Neurosciences in a research note on Wednesday, November 6th.

Minerva Neurosciences Trading Up 0.9 %

Shares of NASDAQ NERV opened at $2.26 on Tuesday. The business’s 50 day moving average is $2.51 and its 200-day moving average is $2.78. Minerva Neurosciences has a 1-year low of $2.07 and a 1-year high of $13.49. The firm has a market cap of $15.80 million, a P/E ratio of -5.14 and a beta of 0.18.

About Minerva Neurosciences

Minerva Neurosciences, Inc, a clinical-stage biopharmaceutical company, focuses on the development and commercialization of product candidates for the treatment of central nervous system diseases. Its lead product candidate is roluperidone (MIN-101) for the treatment of negative symptoms in patients with schizophrenia, currently submitted an New Drug Application (NDA); and MIN-301, a soluble recombinant form of the neuregulin-1b1 protein for the treatment of Parkinson's disease and other neurodegenerative disorders.